GREEN CROSS

Search
Keyword Search
Plasma Derivatives Office Vaccines Subsidiary Pipeline R&D Media Stock Company Recruit
Product Search
close
Total Menu KOR
close

R&DPartnership

Through its wide range of research and development partnerships at home and abroad, Green Cross is working hard to create a brighter future.

Partnership with innovative biotech companies

  • Establishing extensive technical networks with biotech companies that possess promising technologies
  • Securing new, core technologies and ideas in the rapidly changing biotechnology field

Collaboration with academia

  • Securing basic (original) technologies
  • Discovering promising ideas for new drug development
  • Reinforcing R&D pipelines

Cooperation with global leading companies

  • Accumulating expertise in R&D, clinical testing, and licensing
  • Introducing promising candidate substances and forming R&D partnerships
  • Securing global marketing networks

Through its wide range of research and development partnerships at home and abroad, Green Cross is working hard to create a brighter future.

In-licensing

Green Cross has been maximizing the efficacy of its own research institute, and is now realizing open innovation through the creation of R&D synergy based on its dynamic interactions with academia, innovative biotech companies, and leading global pharmaceutical companies. Green Cross continues to secure technical competitiveness in the global biotechnology market and reinforce its R&D pipelines by forming domestic and international partnerships.

Green Cross seeks out collaborative opportunities to develop Green Cross pipeline assets who:

  • have experience and infrastructure related to the development of biological products, including vaccines, plasma derivatives, and recombinant proteins
  • have strong commitments to the development of in-licensed products
  • have experience in and capabilities that can be applied to commercializing in-licensed products
Out-licensing

Collaboration with Green Cross, which has accumulated comprehensive experience in the development of biological drugs, including vaccines, plasma derivatives, and recombinant proteins, gives our partners the opportunity to benefit from our highly experienced research, development, and medical teams, who possess a wide range of scientific, regulatory, clinical, and business capabilities. Not limited to drug development, Green Cross also offers established sales and marketing capabilities across Korean and overseas markets through it diverse distribution channels.

Green Cross is actively exploring partnership opportunities in relation to marked products, platform technologies, and drug candidates under development that are in line with Green Cross’ strategic focus.